Rein Therapeutics Inc
reintx.comWhat Do They Do?
Develops drug candidates for rare lung and fibrosis diseases, including an inhaled therapy for people with idiopathic pulmonary fibrosis.
10-K for FY2025, filed Mar 26, 2026Overview and Recent DevelopmentsView ↗
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis…View ↗
In May 2025, we initiated screening and recruitment of patients in the RENEW Phase 2 clinical trial of LTI-03. The RENEW trial is a Phase 2…View ↗
Who Are Their Customers?
Taiho holds an exclusive license to develop and commercialize LTI-01 in Japan. Rein says it has no marketing, sales or distribution capabilities and may work with established drug companies to commercialize approved products.
10-K for FY2025, filed Mar 26, 2026On November 12, 2020, we entered into a license agreement with Taiho, or the Taiho Agreement, to collaborate on the development and…View ↗
Sales and MarketingView ↗
We currently have no marketing, sales or distribution capabilities. In order to commercialize any products that are approved for commercial…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$6.4MView ↗
- ▼ −7% (Loss)
- vs −$6.8M in Q2 FY2025
-
Aug 27, 2026
Nasdaq issued a delisting notice after Rein fell below its minimum bid-price rule
Rein has until February 17, 2027 to regain compliance; otherwise Nasdaq may begin suspension and delisting procedures.
Sources
8-K, filed Aug 27, 2026
Pursuant to the notice and Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has 180 days from the date of the Notice, or until…View ↗
From oncology to pulmonary disease
The older report centered on an oncology drug candidate for cancer treatment and chemotherapy protection; the latest centers on a lung-fibrosis candidate, with a pleural-effusion candidate and other fibrosis programs also described.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 26, 2026Overview and Recent DevelopmentsView ↗
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis…View ↗
LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of…View ↗
Who Do They Compete With?
Competes with AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, Roche Holding, Novartis, Avalyn Pharma, Vicore Pharma Holding, Endeavor BioMedicines, and PureTech Health
10-K for FY2025, filed Mar 26, 2026There are a number of large biopharmaceutical and biotechnology companies that are currently pursuing the commercialization or development…View ↗
Loading...
